Insider · CIK 0001251213
Ron Bentsur
Files at XAIR (Beyond Air, Inc.), NVCT (Nuvectis Pharma, Inc.). First filing Nov 18, 2024, latest Jul 1, 2026.
In brief
Ron Bentsur files SEC Form 4 as CEO, chair, director and 10% owner at NVCT (Nuvectis Pharma, Inc.), and also at XAIR (Beyond Air, Inc.). Since Nov 18, 2024, Ron Bentsur has reported 4 open-market buys worth $398k and 0 open-market sells worth $0, the latest filed on Jul 1, 2026.
After Ron Bentsur's past buys, the stock beat the S&P 500 by a median 72.3% over six months (n = 3), and 100% of those buys were ahead of the index at six months. InsiderTell labels that a strong record.
The newest scored trade: bought $250k of NVCT on Jun 30, 2026, filed Jul 1, 2026, scored 59 (moderate). In the last 12 months: 2 buys worth $279k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCT: Nuvectis Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | Nuvectis Pharma, Inc. | $250k 12,500 shares | +0% | +225% from low-36% from high | |
| 48Moderate | Nuvectis Pharma, Inc. | $29k 5,000 shares | +0% | +25% from low-49% from high | |
| 33Weak | Nuvectis Pharma, Inc. | $21k 4,500 shares | +0% | - | |
| 38Weak | Nuvectis Pharma, Inc. | $98k 20,000 shares | +1% | - |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +12,500 | $20.00 | $250k | 3,688,424 | Jul 1, 2026 |
| Jan 6, 2026 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 3,675,924 | Jan 9, 2026 |
| Nov 5, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +5,000 | $5.72 | $29k | 3,525,924 | Nov 6, 2025 |
| Jan 2, 2025 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +250,000 | $0.00 | $0 | 3,520,924 | Jan 3, 2025 |
| Dec 24, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +4,500 | $4.65 | $21k | 3,270,924 | Dec 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -45,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +45,000 | - | - | 45,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -40,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +40,000 | - | - | 40,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -30,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +30,000 | - | - | 30,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -25,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +25,000 | - | - | 25,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -25,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +25,000 | - | - | 25,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -24,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +24,000 | - | - | 24,000 | Nov 26, 2024 |
| Nov 15, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +20,000 | $4.92 | $98k | 3,266,424 | Nov 18, 2024 |
Questions about Ron Bentsur
Answered from the filings on this page, as of the latest one.
Is Ron Bentsur buying or selling?
In the last 12 months Ron Bentsur reported 2 open-market buys worth $279k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $250k of NVCT on Jun 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Ron Bentsur's past buys perform?
Measured from the first close after each filing, the stock beat the S&P 500 by a median 72.3% over six months across 3 past buys, with 100% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Ron Bentsur file Form 4?
Ron Bentsur has filed Form 4 at NVCT (Nuvectis Pharma, Inc.) as Chairman & CEO; XAIR (Beyond Air, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.